Tesamorelin vs AOD-9604: Which Targets Belly Fat Better?
Two peptides, one goal: visceral belly fat. Tesamorelin has FDA approval and full GH signaling. AOD-9604 isolates the fat-burning fragment without broader GH effects. Here's how to choose.
Menopause belly fat has two peptide solutions — and they work through fundamentally different mechanisms. Tesamorelin is a GHRH analog that stimulates full growth hormone release from the pituitary, producing broad metabolic effects that include visceral fat reduction. AOD-9604 is a modified fragment of GH (amino acids 177–191) that retains only the fat-metabolizing properties without triggering broader growth hormone effects.
The choice between them depends on what you want beyond fat loss — and what side effects you're willing to manage.
| Feature | Tesamorelin | AOD-9604 |
|---|---|---|
| Mechanism | GHRH analog → full pituitary GH release → lipolysis + metabolic effects | GH fragment → lipolysis + anti-lipogenesis only |
| FDA status | FDA-approved (lipodystrophy) | Category 2 (restricted) |
| Visceral fat reduction | Phase 3 data — significant trunk fat reduction | Phase 2 data — encouraging but less robust |
| IGF-1 elevation | Yes — requires monitoring | No — does not raise IGF-1 |
| Sleep benefits | Yes — GH improves sleep architecture | No — no GH-related sleep effects |
| Skin/collagen effects | Yes — GH supports collagen | No — isolated fat mechanism |
| Blood sugar effects | Possible — GH can affect insulin sensitivity | Minimal — does not affect glucose metabolism |
| Monitoring required | IGF-1, fasting glucose, HbA1c, metabolic panel | Minimal monitoring needed |
| Best for | Women wanting fat loss + broad GH benefits | Women wanting fat loss only, concerned about IGF-1 |
The Verdict
Choose Tesamorelin if: You want the full spectrum of GH benefits (fat loss + sleep + skin + recovery) and are comfortable with IGF-1 monitoring. You want the strongest clinical evidence (FDA approval, Phase 3 data).
Choose AOD-9604 if: You want targeted fat metabolism without broader GH effects. You have concerns about IGF-1 elevation or blood sugar impact. You want a narrower, more predictable intervention.
Consider CJC-1295/Ipamorelin instead if: You want GH benefits but prefer a combined peptide approach that includes sleep and body composition benefits. CJC/Ipa is more commonly prescribed for general perimenopause support; Tesamorelin is more specifically targeted at visceral fat.